Page 72 - SRPSKO DRUŠTVO ISTRAŽIVAČA RAKA

Serbian Association for Cancer Research SDIRSACR

6. Wilschut, J.A.; Habbema, J.D.; van Leerdam, M.E.; Hol, L.; Lansdorp-Vogelaar, I.; Kuipers, E.J.; et al. Fecal occult
blood testing when colonoscopy capacity is limited. J Natl Cancer Inst 2011, 103, 1741-51
7. Quintero, E.; Castells, A.; Bujanda, L.; Cubiella, J.; Salas, D.; Lanas, Á.; et al. Colonoscopy versus fecal immunochemical
testing in colorectal-cancer screening. N Engl J Med 2012, 366, 697-706.
8. Young, G.P.; Rabeneck, L.; Winawer, S.J. The Global Paradigm Shift in Screening for Colorectal Cancer. Gastroenterology
2019, 156, 843-851.
9. Robertson, D.J.; Lee, J.K.; Boland, C.R.; Dominitz, J.A.; Giardiello, F.M.; Johnson, D.A.; et al. Recommendations on
Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society
Task Force on Colorectal Cancer. Gastroenterology 2017, 152, 1217-1237.
10. Murphy, N.; Moreno, V.; Hughes, D.J.; Vodicka, L.; Vodicka, P.; Aglago, E.K.; et al. Lifestyle and dietary environmental
factors in colorectal cancer susceptibility. Mol Aspects Med 2019, 69, 2-9.
11. Lichtenstein, P.; Holm, N.V.; Verkasalo, P.K.; Iliadou, A.; Kaprio, J.; Koskenvuo, M.; et al. Environmental and heritable
factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med
2000, 343, 78-85
12. Frank, C.; Sundquist, J.; Yu, H., Hemminki, A.; Hemminki, K. Concordant and discordant familial cancer: Familial
risks, proportions and population impact. Int J Cancer 2017, 140, 1510-1516.
13. Huyghe, J.R.; Bien, S.A.; Harrison, T.A.; Kang, H.M.; Chen, S.; Schmit, S.L.; et al. Discovery of common and rare
genetic risk variants for colorectal cancer. Nat Genet 2019, 51, 76-87.
14. Law, P.J.; Timofeeva, M.; Fernandez-Rozadilla, C.; Broderick, P.; Studd, J.; Fernandez-Tajes, J.; et al. Association
analyses identify 31 new risk loci for colorectal cancer susceptibility. Nat Commun 2019, 10, 2154.
15. Kraft, P.; Wacholder, S.; Cornelis, M.C.; Hu, F.B.; Hayes, R.B.; Thomas, G.; et al. Beyond odds ratios–communicating
disease risk based on genetic profiles. Nat Rev Genet 2009, 10, 264-9.
16. Dunlop, M.G.; Tenesa, A.; Farrington, S.M.; Ballereau, S.; Brewster, D.H.; Koessler, T.; et al. Cumulative impact of
common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals. Gut 2013; 62, 871-81
17. Jeon, J.; Du, M., Schoen, R.E.; Hoffmeister, M.; Newcomb, P.A.; Berndt, S.I.; et al. Determining Risk of Colorectal
Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. Gastroenterology
2018, 154, 2152-2164.
18. Thomas, M.; Sakoda, L.C.; Hoffmeister, M.; Rosenthal, E.A.; Lee, J.K.; van Duijnhoven, F.J.B.; et al. Genome-wide
Modeling of Polygenic Risk Score in Colorectal Cancer Risk. Am J Hum Genet 2020, 107, 432-444
19. Khera, A.V.; Chaffin, M.; Aragam, K.G.; Haas, M.E.; Roselli, C.; Choi, S.H.; et al. Genome-wide polygenic scores for
common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 2018, 50, 1219-
1224.
20. Frampton, M.J.; Law, P.; Litchfield, K.; Morris, E.J.; Kerr, D.; Turnbull, C.; et al. Implications of polygenic risk for
personalised colorectal cancer screening. Ann Oncol 2016, 27, 429-34.
21. Weigl, K.; Thomsen, H.; Balavarca, Y.; Hellwege, J.N.; Shrubsole, M.J.; Brenner, H. Genetic Risk Score Is Associated
With Prevalence of Advanced Neoplasms in a Colorectal Cancer Screening Population. Gastroenterology 2018, 155,
88-98.
22. Guo, F.; Weigl, K.; Carr, P.R.; Heisser, T.; Jansen, L.; Knebel, P.; et al. Use of Polygenic Risk Scores to Select Screening
Intervals After Negative Findings From Colonoscopy. Clin Gastroenterol Hepatol 2020, 18, 2742-2751.

Acknowledgments and funding: This research was supported by grants from the Horizon Europe project STEPUPIORS
(101079217; HORIZON-WIDERA-2021-ACCESS-03), Fondo de Investigación Sanitaria/FEDER (20/00113, 20/00226,
23/00189), La Marató TV3 2019 (202008-10), Asociación Española Contra el Cáncer (PRYGN211085CAST), COST Action
CA17118, “la Caixa” Foundation (agreement LCF/PR/SP23/52950009), CERCA Programme (Generalitat de Catalunya)
and Agència de Gestió d'Ajuts Universitaris i de Recerca (Generalitat de Catalunya, 2021 SGR 01185). This work is
supported (not financially) by the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS).
ERN GENTURIS is funded by the European Union. CIBEREHD is funded by the Instituto de Salud Carlos III.
We are sincerely grateful to the patients, CNAG and Biobanks of all collaborating centers (Biobank of Hospital Clínic–
IDIBAPS, Euskal Biobankoa), as well as to the Genomics facility of the Fundació de Recerca Clínic Barcelona-Institut
d’Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS) for the technical help. This work was developed (in
part) at the Esther Koplowitz Centre.

57